Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Key facts

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Intervention

Tafasitamab(drug)

Enrollment

244 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (20)

• Beijing Hospital, Beijing, China
• The First Hospital Of Jilin University, Changchun, China
• Hunan Cancer Hospital, Changsha, China
• Chenzhou No.1 People's Hospital, Chaozhou, China
• Sichuan Province People's Hospital, Chengdu, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
• Guangdong General Hospital, Guangzhou, China
• Sun Yat-sen University Cancer Center, Guangzhou, China
• Hangzhou First People's Hospital, Hangzhou, China
• The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
• Shandong Cancer Hospital and Institute, Jinan, China
• Jiangxi Cancer Hospital, Nanchang, China
• The First Affiliated Hospital of Nanchang University, Nanjing, China
• Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
• The Second Affiliated Hospital of Soochow University, Suzhou, China
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07365306
  Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE3NCT07493109
  Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
  Ou Bai, MD/PHD
• RECRUITINGPHASE2NCT07493148
  Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
  Ou Bai, MD/PHD
• RECRUITINGPHASE3NCT07409428
  A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
  Hutchmed
• RECRUITINGPHASE2NCT07397832
  CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE3NCT07188558
  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
  Lyell Immunopharma, Inc.
• RECRUITINGPHASE2NCT07499271
  Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT07189065
  A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
  Guangzhou Lupeng Pharmaceutical Company LTD.

See all trials for Diffuse large B-cell lymphoma →